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Objective. Interstitial lung disease (ILD) is the leading cause of death in patients with systemic sclerosis (SSc). 
Although pulmonary function tests (PFTs) are commonly used to screen for ILD in patients with SSc, studies have 
shown that they lack sensitivity for the detection of ILD in general SSc cohorts. This study was undertaken to assess 
the performance characteristics of PFTs for the detection of ILD in patients with early diffuse cutaneous SSc (dcSSc), 
a population at high risk for the development of ILD.
Methods. We performed a retrospective cohort study of patients enrolled in the Prospective Registry of Early 
Systemic Sclerosis at 11 sites in the US between April 2012 and January 2019. Patients were included if they 
underwent spirometry and high-resolution computed tomography (HRCT) of the chest. We calculated the performance 
characteristics of PFTs for the detection of ILD on HRCT.
Results. The study included 212 patients, 54% of whom had radiographic ILD. For the detection of ILD on HRCT 
imaging, a forced vital capacity (FVC) <80% predicted had a sensitivity of 63%. The combination of FVC <80% 
predicted or diffusing capacity for carbon monoxide (DLco) <80% predicted improved the sensitivity to 85%. An FVC 
<80% predicted had a negative predictive value (NPV) of 61%, while the combination of FVC <80% predicted or 
DLco <80% predicted had an NPV of 70%.
Conclusion. PFTs alone are an inadequate screening tool for the diagnosis of ILD in patients with early dcSSc. 
HRCT should be part of the ILD screening algorithm in patients with dcSSc.
INTRODUCTION
Interstitial lung disease (ILD) is a prevalent complication of 
systemic sclerosis (SSc), affecting 40–60% of patients with this 
disease, and is the leading cause of death in patients with SSc 
(1–4). SSc patients with severe ILD have the greatest loss of lung 
volume early in the disease course (1). Scleroderma Lung Study II 
has demonstrated that SSc patients with early ILD can experience 
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improvement in lung function and quantitative ILD score on 
high-resolution computed tomography (HRCT) of the chest when 
receiving aggressive treatment with either mycophenolate mofetil 
or cyclophosphamide (5). However, there are no screening guide-
lines for ILD in patients with SSc. Moreover, although HRCT is the 
gold standard diagnostic test for the detection of ILD, there is no 
consensus among rheumatologists regarding the use of HRCT 
to screen for ILD in their SSc patients. For example, in a survey 
of both general rheumatologists and SSc experts, Bernstein et al 
found that only 51% of general rheumatologists and 66% of SSc 
experts reported routinely ordering HRCT scans in their newly 
diagnosed SSc patients (6).
Although pulmonary function tests (PFTs) are frequently 
used by rheumatologists as a screening test for ILD in their 
patients with SSc, studies have shown that they lack sensitiv-
ity for the detection of ILD in a general population of patients 







Age years 51.7 ± 13.8 53.1 ± 13.0 50.1 ± 14.5
Female sex, no. (%) 144 (67.9) 74 (64.3) 70 (72.2)
Race, no. (%)
White 161 (75.9) 82 (71.3) 79 (81.4)
African American 31 (14.6) 21 (18.3) 10 (10.3)
Asian 9 (4.2) 6 (5.2) 3 (3.1)
Hispanic 23 (10.8) 13 (11.3) 10 (10.3)
Smoking status, no. (%)
Never 128 (60.4) 70 (60.9) 58 (59.8)
Former 70 (33) 37 (32.2) 33 (34.0)
Current 14 (6.6) 8 (7.0) 6 (6.2)
Disease duration from first non-Raynaud’s symptom, years 1.2 ± 0.7 1.3 ± 0.7 1.2 ± 0.6
Modified Rodnan skin thickness score 20.8 ± 10.3 (207) 20 ± 9.9 (113) 21.8 ± 10.7 (94)
Antibody positivity, no./no. assessed (%)
Antinuclear antibody positive 169/183 (92.3) 89/98 (90.8) 80/85 (94.1)
Anti-topoisomerase I antibody positive 57/177 (32.2) 40/97 (41.2) 17/80 (21.2)
Anti-RNA polymerase III antibody positive 79/160 (49.4) 37/85 (43.5) 42/75 (56.0)
Anticentromere antibody positive 3/150 (2) 1/85 (1.2) 2/65 (3.1)
Antifibrillarin antibody positive 1/46 (2.2) 0/22 (0) 1/24 (4.2)
Anti-Th/To antibody positive 5/44 (11.4) 2/23 (8.7) 3/21 (14.3)
PFTs
FVC, liters 3.1 ± 1.6 (211) 2.9 ± 0.9 (114) 3.4 ± 2.1 (97)
FVC, % predicted 80.4 ± 18.8 (212) 76.1 ± 18.7 (115) 85.5 ± 17.8 (97)
FEV1, liters 2.8 ± 5.8 (209) 3.1 ± 7.8 (113) 2.6 ± 0.7 (96)
FEV1, % predicted 83.4 ± 19.8 (210) 79.4 ± 18.9 (114) 88.2 ± 19.7 (96)
FEV1/FVC ratio 84.3 ± 10.9 (194) 85.3 ± 11.3 (107) 83 ± 10.3 (87)
TLC, liters 5 ± 3.2 (148) 4.6 ± 1.2 (85) 5.7 ± 4.7 (63)
TLC, % predicted 86.7 ± 20.4 (146) 83.6 ± 20.3 (85) 91.1 ± 20.0 (61)
DLco, % predicted 68.4 ± 24.4 (199) 60.5 ± 22.2 (109) 78 ± 23.5 (90)
Absolute time between PFTs and HRCT imaging, years 0.3 ± 0.4 (211) 0.3 ± 0.4 (115) 0.3 ± 0.4 (96)
Absolute time between PFTs and HRCT imaging, median (IQR) years (no. assessed) 0.1 (0–0.4) (211) 0.1 (0–0.4) (115) 0.1 (0–0.4) (96)
Treatments
Mycophenolate mofetil, no. (%) 83 (39.2) 50 (43.5) 33 (34.0)
Prednisone, no. (%) 68 (32.1) 33 (28.7) 35 (36.1)
Methotrexate, no. (%) 28 (13.2) 13 (11.3) 15 (15.5)
Hydroxychloroquine, no. (%) 27 (12.7) 15 (13) 12 (12.4)
Cyclophosphamide, no. (%) 6 (2.8) 4 (3.5) 2 (2.1)
D-penicillamine, no. (%) 5 (2.4) 2 (1.7) 3 (3.1)
Azathioprine, no. (%) 4 (1.9) 4 (3.5) 0 (0)
Investigational drug, no./no. assessed (%) 6/211 (2.8) 2/114 (1.8) 4/97 (4.1)
Supplemental oxygen use, no./no. assessed (%) 4/211 (1.9) 3/114 (2.6) 1/97 (1)
New York Heart Association Functional Class, no./no. assessed (%)
I 88/195 (45.1) 43/107 (40.2) 45/88 (51.1)
II 73/195 (37.4) 44/107 (41.1) 29/88 (33)
III 34/195 (17.4) 20/107 (18.7) 14/88 (15.9)
IV 0/195 (0) 0/107 (0) 0/88 (0)
SHAQ breathlessness score 2.2 ± 2.8 (175) 2.5 ± 3 (94) 1.8 ± 2.5 (81)
* Except where indicated otherwise, values are the mean ± SD (no. assessed). PRESS = Prospective Registry of Early Systemic Sclerosis; ILD = 
interstitial lung disease; PFTs = pulmonary function tests; FVC = forced vital capacity; FEV1 = forced expiratory volume in 1 second; TLC = total 
lung capacity; DLco = diffusing capacity for carbon monoxide; HRCT = high-resolution computed tomography; IQR = interquartile range; SHAQ = 
Scleroderma Health Assessment Questionnaire. 
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with SSc (4,7). For example, in a cross-sectional study of 102 
patients with SSc (41% with diffuse cutaneous SSc [dcSSc]) 
with a median disease duration of 6 years (interquartile range 
[IQR] 3–12.5 years), a forced vital capacity (FVC) <80% predicted 
had a sensitivity of only 37.5% for the detection of ILD on HRCT 
imaging (4). Having an FVC <80% predicted or a diffusing capac-
ity for carbon monoxide (DLco) <70% predicted only improved 
the sensitivity to 59% (4). The aim of this study was to assess the 
performance characteristics of PFTs for the detection of ILD on 
HRCT in patients with early dcSSc—arguably the SSc patients 
at greatest risk for ILD.
PATIENTS AND METHODS
Study population. The Prospective Registry of Early Sys-
temic Sclerosis (PRESS) is a multicenter, prospective cohort study 
of adults with early dcSSc (disease duration <2 years from the onset 
of the first non–Raynaud’s phenomenon [RP] symptom) who met 
the American College of Rheumatology/European League Against 
Rheumatism 2013 classification criteria for SSc (8). Enrollment 
began in April 2012 and is ongoing. Participants were recruited 
from 11 academic medical centers in the US: Columbia University, 
Georgetown University, George Washington University, Hospital for 
Special Surgery, Johns Hopkins University, Medical University of 
South Carolina, Northwestern University, University of Michigan, 
University of Pittsburgh, University of Texas Health Science Center 
at Houston, and University of Utah. The University of Michigan is 
the data coordinating center. All participants enrolled in PRESS 
between April 2012 and January 2019 who underwent spirometry 
and HRCT were included. This study was approved by the institu-
tional review boards at each of the 11 participating sites. All par-
ticipants in the PRESS cohort provided written informed consent.
PFTs and HRCT. PFTs were performed at each PRESS site 
in accordance with American Thoracic Society (ATS)/European 
Respiratory Society (ERS) guidelines (9–11), as clinically indicated. 
The lower limit of normal for FVC, total lung capacity (TLC), and 
DLco was defined as 80% predicted. HRCT scans were ordered 
at the discretion of the treating physician and were interpreted 
by expert thoracic radiologists at each PRESS site, according to 
ATS/ERS standards (12,13), for the presence or absence of ILD. 
The local expert thoracic radiologists visually inspected partici-
pants’ HRCT scans for the presence of ILD characteristics, includ-
ing ground glass opacities, reticular changes, honeycombing, and 
traction bronchiectasis. For each participant, the first set of PFTs 
and the first HRCT image were used in the analyses.
Statistical analysis. The following test characteristics of 
single PFT parameters and combinations of PFT parameters to 
detect ILD on HRCT were calculated: sensitivity, specificity, posi-
tive predictive value, negative predictive value (NPV), positive likeli-
hood ratio (LR), negative LR, false-positive rate, and false-negative 
rate (FNR). Analyses were performed using R, version 3.5.2 
(R Foundation for Statistical Computing).
RESULTS
Two hundred eighty-three adults with dcSSc were enrolled in 
the PRESS study between April 2012 and January 2019, of whom 
212 (75%) underwent spirometry and HRCT, had available HRCT 
interpretations, and were included in the analyses. The mean ± SD 
disease duration was 1.2 ± 0.7 years from the first non–RP symp-
tom attributable to SSc at PRESS cohort entry. The mean ± SD 
age of the participants was 51.7 ± 13.8 years, and the majority 
were female (67.9%). Patients had a mean ± SD modified Rod-
nan skin thickness score of 20.8 ± 10.3. Of the patients included, 
32.2% were positive for the anti–topoisomerase I antibody, and 
49.4% were positive for the anti–RNA polymerase III antibody. 
The mean ± SD FVC was 80.4 ± 18.8 % predicted, the mean ± SD 
TLC was 86.7 ± 20.4 % predicted, and the mean ± SD DLco was 
68.4 ± 24.4 % predicted (Table 1). Fifty-four percent of the partic-
ipants had radiographic evidence of ILD, including ground glass 
opacities (85 of 110 [77%]), reticular changes (60 of 97 [62%]), 
and/or honeycombing (8 of 106 [7.5%]). Of the 115 participants 
with radiographic ILD, only 63% had an FVC <80% predicted. 
The median absolute time between PFTs and HRCT was 0.1 
years (IQR 0–0.4 years).
Among participants with ILD, those with an FVC ≥80% pre-
dicted (i.e., false-negatives) had a shorter disease duration than 
those with an FVC <80% predicted (i.e., true-positives) (mean ± SD 
1.0 ± 0.6 versus 1.4 ± 0.8 years) (Table 2). Among participants with 
ILD, a greater proportion of those with an FVC ≥80%  predicted 
were female and white compared to those with an FVC <80% 
 predicted (76.7% versus 56.9%; and 83.7% versus 63.9%, respec-
tively) (Table 2). Conversely, a greater proportion of those with an 
FVC <80% predicted than those with an FVC ≥80%  predicted 
were African American (27.8% versus 2.3%) (Table 2).
For the detection of ILD on HRCT, an FVC <80% predicted 
had a sensitivity of 63%, a TLC <80% predicted had a sensitiv-
ity of 46%, and a DLco <80% predicted had a sensitivity of 80%. 
The combination of FVC <80% predicted or DLco <80% predicted 
improved the sensitivity to 85%. Adding a TLC <80% predicted to 
this combination (i.e., FVC <80% predicted, TLC <80% predicted, 
or DLco <80% predicted) did not further improve the sensitivity 
(Table 3).
An FVC <80% predicted had an NPV of 61% in this early 
dcSSc patient population with an ILD prevalence of 54%. A DLco 
<80% predicted had an NPV of 68%, while the combination of 
FVC <80% predicted or DLco <80% predicted had an NPV of 
70%. An FVC <80% predicted had a negative LR of 0.5 and an 
FNR of 37%, while a DLco <80% predicted had a negative LR of 
0.4 and an FNR of 20%. The combination of FVC <80% predicted 
or DLco <80% predicted had a negative LR of 0.4 and an FNR of 
15% (Table 3).
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DISCUSSION
We found that DLco <80% predicted had better sensitivity 
than FVC <80% predicted or TLC <80% predicted for the detec-
tion of ILD on HRCT scans in patients with early dcSSc. The 
combination of FVC <80% predicted or DLco <80% predicted 
performed better than any individual parameter, with a sensitivity 
of 85% for the detection of ILD on HRCT in this population. We 
demonstrated that spirometry alone is an insufficient screening tool 
for ILD in patients with dcSSc, as evidenced by a sensitivity of 
63% and an FNR of 37% for an FVC <80% predicted. Although a 
decreased DLco in patients with a longer disease duration is likely 
to reflect pulmonary vascular disease, this is an unlikely etiology for 
a decreased DLco in this group of patients with early dcSSc. Thus, 
when employing PFTs as a screening tool for the detection of early 
ILD in patients with dcSSc, it is important to check the DLco in 
addition to spirometry. Moreover, although a sensitivity of 85% is 
reasonable, it is inadequate for an ILD screening test, as it results 
in an FNR of 15%, thereby falsely reassuring 15% of patients that 
they do not have ILD when in fact they do. The NPV is, arguably, an 
even more important screening test characteristic than sensitivity 
because it is affected by disease prevalence (14). We found that an 
Table 2. Comparison of baseline characteristics between patients with SSc-ILD with FVC ≥80% predicted and FVC 
<80% predicted*
FVC ≥80% and ILD 
(n = 43)
FVC <80% and ILD 
(n = 72)
Age, years 54.7 ± 11.7 52.1 ± 13.7
Female sex, no. (%) 33 (76.7) 41 (56.9)
Race, no. (%)
White 36 (83.7) 46 (63.9)
African American 1 (2.3) 20 (27.8)
Asian 4 (9.3) 2 (2.8)
Hispanic 3 (7.0) 10 (13.9)
Smoking status, no. (%)
Never 25 (58.1) 45 (62.5)
Former 16 (37.2) 21 (29.2)
Current 2 (4.7) 6 (8.3)
Disease duration from first non-Raynaud’s symptom, years 1.0 ± 0.6 1.4 ± 0.8
Modified Rodnan skin score 19.1 ± 9.7 (43) 20.5 ± 10.0 (70)
Antinuclear antibody positive, no./no. assessed (%) 32/36 (88.9) 57/62 (91.9)
Anti-topoisomerase I antibody positive, no./no. assessed (%) 13/35 (37.1) 27/62 (43.5)
Anti-RNA polymerase III antibody positive, no./no. assessed (%) 17/32 (53.1) 20/53 (37.7)
Anticentromere antibody positive, no./no. assessed (%) 0/32 (0) 1/53 (1.9)
FVC, liters 3.4 ± 0.8 (43) 2.6 ± 0.7 (71)
FVC, % predicted 96.8 ± 9.6 63.7 ± 9.6
FEV1, liters 4.6 ± 12.6 (43) 2.1 ± 0.6 (70)
FEV1, % predicted 95.2 ± 17.9 (43) 69.7 ± 11.8 (71)
FEV1/FVC ratio 80.1 ± 8.5 (41) 88.5 ± 11.7 (66)
TLC, liters 5.3 ± 1.0 (36) 4.1 ± 1.0 (49)
TLC, % predicted 102.0 ± 12.3 (36) 70.1 ± 13.0 (49)
DLco, % predicted 74.8 ± 20.3 (42) 51.5 ± 18.4 (67)
New York Heart Association Functional Class, no. (%) 41 66
I 21 (51.2) 22 (33.3)
II 16 (39.0) 28 (42.4)
III 4 (9.8) 16 (24.2)
IV 0 (0) 0 (0)
SHAQ breathlessness score 1.6 ± 2.2 (35) 3.1 ± 3.3 (59)
* Except where indicated otherwise, values are the mean ± SD (no. assessed). SSc = systemic sclerosis; ILD = interstitial 
lung disease; FVC = forced vital capacity; FEV1 = forced expiratory volume in 1 second; TLC = total lung capacity; DLco = 
diffusing capacity for carbon monoxide; SHAQ = Scleroderma Health Assessment Questionnaire. 
Table 3. Performance characteristics of pulmonary function tests for the detection of interstitial lung disease*
PFT parameter No. of patients Sensitivity, % Specificity, % PPV, % NPV, % Positive LR Negative LR FPR FNR
FVC <80% 212 63 68 70 61 2.0 0.5 0.32 0.37
TLC <80% 146 46 77 74 51 2.0 0.7 0.23 0.54
DLco <80% 200 80 51 66 68 1.6 0.4 0.49 0.20
FVC or DLco <80% 199 85 42 64 70 1.5 0.4 0.58 0.15
FVC or TLC or DLco <80% 143 85 42 68 66 1.5 0.4 0.58 0.15
* PFT = pulmonary function test; PPV = positive predictive value; NPV = negative predictive value; LR = likelihood ratio; FPR = false-positive 
rate; FNR = false-negative rate; FVC = forced vital capacity; TLC = total lung capacity; DLco = diffusing capacity for carbon monoxide. 
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FVC <80% predicted had an NPV of 61%, while the combination 
of FVC <80% predicted or DLco <80% predicted only improved 
the NPV to 70%. Thus, patients with early dcSSc who have “nor-
mal” PFTs only have a 70% probability of not having ILD on HRCT.
A recent study of all 815 resident SSc patients in Norway 
(of whom 80% had baseline HRCT scans and 86% had baseline 
PFTs)—only 18% of whom had dcSSc—from 2000 to 2012 found 
that at baseline, 50% of the patients with SSc had radiographic 
evidence of ILD on HRCT (15). Moreover, for the 77 patients 
who had a radiographic ILD extent of >10%, the mean ± SD 
FVC was 78 ± 19% predicted. Of these 77 patients, ~17% had 
an FVC >100% predicted, and ~43% had an FVC of 70–100% 
predicted (15). For the 249 patients who had a radiographic ILD 
extent of <10%, the mean ± SD FVC was 91 ± 21% predicted, 
~40% had an FVC >100% predicted, and ~50% had an FVC of 
70–100% predicted (15). In addition, among patients with an FVC 
in the normal range of 80–100% predicted, both those with a 
ra diographic ILD extent of <10% and those with a radiographic ILD 
extent of >10% on baseline HRCT had significantly diminished sur-
vival compared to those without fibrosis on HRCT (63% and 62%, 
respectively, versus 82%; P = 0.01) (15). Thus, baseline HRCT 
imaging has important prognostic value, even among patients with 
FVCs in the normal range (15). The mere presence of SSc-related 
ILD on baseline HRCT is associated with increased mortality.
There are some limitations of this study. HRCT scans and 
PFTs were not performed in all PRESS patients and were instead 
ordered at the discretion of their treating physicians. Notably, how-
ever, 92% and 93% of patients in the PRESS cohort underwent 
HRCT and PFTs, respectively, as part of clinical care. The preva-
lence of ILD in other dcSSc patient populations is likely similar to 
the prevalence of ILD in our study population; thus, our results 
are generalizable to other dcSSc patients who undergo both 
PFTs and HRCT. Centralized reading of participants’ HRCT scans 
was not performed. However, HRCT images were interpreted 
by expert thoracic radiologists at each PRESS site according to 
ATS/ERS standards (12,13). ILD extent was not quantified; thus, 
we were unable to categorize and analyze patients according to 
 disease extent.
The present study has several strengths. To our knowledge, 
PRESS is the largest cohort comprised solely of, and therefore 
focused specifically on, patients with early dcSSc. We were there-
fore able to address an important question, i.e., the predictive 
value of PFTs for the radiographic detection of ILD, in a group 
at high risk for the development of ILD. The PRESS investiga-
tors are all experienced in the conduct of observational studies 
and  clinical trials in patients with SSc and were therefore able to 
 collect,  prospectively, robust phenotypic data.
In conclusion, we demonstrated that PFTs lack sufficient 
sensitivity and NPV for the detection of ILD on HRCT in patients 
with early dcSSc. We therefore recommend that all patients with 
dcSSc undergo baseline HRCT, in addition to PFTs, to screen for 
ILD.
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